# EPCORE DLBCL-2

Source: https://onco.cc/trials/epcore-dlbcl-2/  
OnCo record `epcore-dlbcl-2` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Tests whether adding a bispecific to first-line chemotherapy cures more patients up front.

## Summary

EPCORE DLBCL-2, trial NCT05578976 sponsored by Genmab and AbbVie, tests whether adding a fixed duration of the bispecific epcoritamab to first-line R-CHOP cures more patients with untreated diffuse large B-cell lymphoma up front. Topline results were announced in 2026 and presented at EHA 2026, and together with frontMIND and POLARIX the trial defines the frontline options for higher-risk disease. OnCo links it to lymphoma and epcoritamab. Whether a T-cell engager added to chemotherapy improves cure rates enough to justify its toxicity and cost in the first line is the question its data will answer.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-07
- Registry id: NCT05578976
- Phase: 3
- Setting: Untreated DLBCL: epcoritamab + R-CHOP vs R-CHOP
- Sponsor: Genmab / AbbVie

## Sources

- ClinicalTrials.gov NCT05578976: https://clinicaltrials.gov/study/NCT05578976

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- technologies: [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- drugs: [Epcoritamab](https://onco.cc/drugs/epcoritamab/)
- companies: [Genmab](https://onco.cc/companies/genmab/)
- ideas: [ctDNA-guided escalation and de-escalation in frontline DLBCL](https://onco.cc/ideas/idea-ctdna-guided-dlbcl-frontline/)

---
JSON: https://onco.cc/api/v1/entities/epcore-dlbcl-2.json